Missed Diagnosis and Misdiagnosis: Optimizing Management of Diabetic Gastroparesis

CMEO Medical Meeting

Symposium Date: Monday, May 20, 2019
Hilton San Diego Bayfront
Indigo A/B
1 Park Boulevard
San Diego, CA 92101

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Wednesday, May 20, 2020

Register for Activity

Faculty


Satish S.C. Rao, MD, PhD, FRCP (LON), FACG, AGAF Satish S.C. Rao, MD, PhD, FRCP (LON), FACG, AGAF (Moderator)
J. Harold Harrison, MD, Distinguished University Chair in Gastroenterology
Professor of Medicine
Director, Neurogastroenterology & Motility
Director, Digestive Health Clinical Research Center Augusta, GA

Michael Camilleri, MD Michael Camilleri, MD 
Atherton and Winifred W. Bean Professor
Professor of Medicine, Pharmacology, and Physiology
Mayo Clinic College of Medicine and Science
Rochester, MN

Statement of Need

Diabetic gastroparesis is a chronic and debilitating condition characterized by delayed gastric emptying in the absence of mechanical obstruction, and it effects up to 40% of patients with diabetes. Coinciding with the increased incidence of diabetes, particularly type 2 diabetes, the rate of hospitalizations secondary to diabetic gastroparesis rose by 138% from 1995 to 2004.

The pathology of gastroparesis is poorly understood, and the condition is frequently misdiagnosed, leading to afflicted patients suffering from a plethora of symptoms, reporting poor quality of life (QoL) and frequent hospitalizations. Treatment has been suboptimal and unchanged over the last 40 years, with just one FDA-approved medication for gastroparesis; however, as knowledge about this condition increases, new drug targets are being discovered, and clinician education is needed to adequately serve patients who suffer from diabetic gastroparesis.

This CME Outfitters symposium features interactive 3-D animation. Our expert faculty will use this visualization to discuss the role of ghrelin in GI motility. Faculty will further review the signs, symptoms, and diagnostic tests for diabetic gastroparesis, as well as evaluate the clinical efficacy and safety profiles of current and emerging agents for managing this condition.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Review the signs, symptoms, and diagnostic tests for diabetic gastroparesis.
  • Analyze the role of ghrelin in promoting GI motility associated with diabetic gastroparesis.
  • Evaluate the clinical efficacy and safety profiles of current and emerging agents for the management of diabetic gastroparesis.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Review the signs, symptoms, and diagnostic tests for diabetic gastroparesis.
  • Analyze the role of ghrelin in promoting GI motility associated with diabetic gastroparesis.
  • Review the clinical efficacy and safety profiles of current and emerging agents for the management of diabetic gastroparesis.

Financial Support

Supported by an educational grant from Allergan.

Target Audience

Gastroenterologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15) CEUs). Universal Activity Number:
Live: 0376-0000-19-020-L01-P

Type: knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST28515 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy/

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Rao reports that he receives research support from Covidien; Forest Laboratories; Progenix; Seres Therapeutics; Valeant Pharmaceuticals; and Vibrant Pharma Inc. He is a consultant for Forest Laboratories; InControl Medical, LLC; Ironwood Pharmaceuticals; Progenix; and Sucampo Pharmaceuticals, Inc. He is on the advisory board for Forest Laboratories; InControl Medical LLC; Ironwood Pharmaceuticals; Progenix; QuinTron Instrument Company Inc.; Sucampo Pharmaceuticals, Inc.; Synergy Pharmaceuticals Inc.; Valeant Pharmaceuticals; and Vibrant Pharma Inc.

Dr. Camilleri reports that he receives research support from Allergan; Rhythm Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is on the advisory committee for Allergan (no personal remuneration). He is an advisor to Takeda Pharmaceuticals, Inc. (no personal remuneration, payment made to Mayo Clinic).

Kate Nelson, PHD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MM-093-052019-03